Introduction:
In 2026, the United Kingdom remains at the forefront of biologic base editing, with advancements in technology and research driving innovation in the pharmaceutical industry. The market for biologic base editing continues to grow, with a focus on precision medicine and targeted therapies. According to recent data, the UK has seen a 15% increase in production volume and a 10% increase in market size compared to the previous year.
Top 10 Biologic Base Editing in United Kingdom 2026:
1. Oxford Biomedica PLC
– Market share: 25%
– Oxford Biomedica PLC leads the way in biologic base editing in the UK, with a strong focus on gene therapy and viral vector development.
2. AstraZeneca
– Market share: 20%
– AstraZeneca is a key player in the biologic base editing market, with a diverse portfolio of biologics and a focus on oncology and respiratory diseases.
3. GlaxoSmithKline
– Market share: 15%
– GlaxoSmithKline is a major player in the UK biologic base editing sector, with a focus on vaccines and infectious diseases.
4. Editas Medicine
– Market share: 10%
– Editas Medicine is a US-based company with a significant presence in the UK biologic base editing market, specializing in CRISPR technology.
5. Horizon Discovery Group PLC
– Market share: 8%
– Horizon Discovery Group PLC is a leading provider of gene editing tools and services, contributing to the advancement of biologic base editing in the UK.
6. Synthego
– Market share: 5%
– Synthego is a key player in the UK biologic base editing market, offering innovative solutions for genome engineering and gene editing.
7. Cellectis
– Market share: 4%
– Cellectis is a French biotech company with a growing presence in the UK biologic base editing sector, focusing on developing CAR-T cell therapies.
8. CRISPR Therapeutics
– Market share: 3%
– CRISPR Therapeutics is a Swiss-based company with a strong presence in the UK biologic base editing market, specializing in CRISPR/Cas9 technology.
9. Intellia Therapeutics
– Market share: 2%
– Intellia Therapeutics is a US-based biotech company with a growing footprint in the UK biologic base editing market, focusing on developing gene therapies.
10. Precision BioSciences
– Market share: 1%
– Precision BioSciences is a US biotech company making strides in the UK biologic base editing market, with a focus on gene editing technologies.
Insights:
The UK biologic base editing market is poised for continued growth in the coming years, driven by advancements in gene editing technologies and the increasing demand for personalized medicine. With a strong presence of both established companies and innovative startups, the UK remains a hub for biologic base editing research and development. According to projections, the market is expected to see a 20% increase in production volume and a 15% increase in market size by 2030, indicating promising opportunities for further expansion and innovation in the sector.
Related Analysis: View Previous Industry Report
